Hepatitis C therapy update

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations


Purpose of Review: We review here the recent literature regarding hepatitis C treatment through January 2012. We discuss newly approved therapies and their clinical trial data and discuss what can be expected in this rapidly changing field. Recent Findings: Two new directly acting antiviral agents were approved in 2011 for use in hepatitis C treatment, bringing shortened treatment durations, and increased treatment success to some patients with genotype 1 hepatitis C. Additional drugs using different viral targets are in development to further improve response rates, tolerance, and increase access to therapy. Summary: Telaprevir and boceprevir were approved in 2011 for use against genotype 1 hepatitis C, in combination with pegylated interferon and ribavirin. In most populations of genotype 1 patients, response rates are much improved but increased treatment related anemia has been seen. Additional options for therapy, including interferon-free regimens, are still needed and are under development.

Original languageEnglish (US)
Pages (from-to)188-192
Number of pages5
JournalCurrent Opinion in Gastroenterology
Issue number3
StatePublished - May 2012


  • boceprevir
  • direct-acting antivirals
  • hepatitis C virus
  • protease inhibitor
  • telaprevir

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Hepatitis C therapy update'. Together they form a unique fingerprint.

Cite this